Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30303325 | 1.00 | BTK (0.49) | BTKEGFRKCNH2MAP2K7ERBB2 | |
| SCHEMBL22676043 | 0.88 | CYP3A4 (0.44) | EGFR | |
| SCHEMBL22676839 | 0.87 | SLC2A1 (0.41) | EGFR | |
| SCHEMBL30303388 | 0.87 | SLC2A1 (0.41) | EGFR | |
| SCHEMBL22676050 | 0.85 | JAK3 (0.39) | BTKEGFRKCNH2ERBB2 | |
| SCHEMBL30303700 | 0.85 | JAK3 (0.39) | BTKEGFRKCNH2ERBB2 | |
| SCHEMBL22675958 | 0.84 | MAP2K7 (0.44) | BTKEGFRKCNH2MAP2K7ERBB2 | |
| SCHEMBL22676078 | 0.83 | FGFR1 (0.51) | BTKEGFRKCNH2MAP2K7ERBB2 | |
| SCHEMBL22677214 | 0.81 | TGM2 (0.55) | BTKEGFRKCNH2MAP2K7ERBB2 | |
| SCHEMBL25715071 | 0.80 | BTK (0.49) | BTKEGFRKCNH2MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | BTK 39/4885EGFR 16/4885KCNH2 4772/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | BTK 39/4885EGFR 16/4885KCNH2 4772/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | BTK 39/4885EGFR 16/4885KCNH2 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.